← Back to home

Advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) with MET exon 14 (METEX14) skipping alterations or MET amplification

Clinical trials for Advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) with MET exon 14 (METEX14) skipping alterations or MET amplification explained in plain language.

Never miss a new study

Get alerted when new Advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) with MET exon 14 (METEX14) skipping alterations or MET amplification trials appear

Sign up with your email to follow new studies for Advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) with MET exon 14 (METEX14) skipping alterations or MET amplification, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New targeted drug shows promise for lung cancer with MET mutations

Disease control Ongoing

This trial tested the drug tepotinib in 337 people with advanced non-small cell lung cancer that has specific MET gene changes (METex14 skipping or MET amplification). Participants took a 500 mg pill once daily. The main goal was to see if the drug could shrink tumors. The study …

Matched conditions: ADVANCED (STAGE IIIB/IV) NON-SMALL CELL LUNG CANCER (NSCLC) WITH MET EXON 14 (METEX14) SKIPPING ALTERATIONS OR MET AMPLIFICATION

Phase 2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control

Last updated Jul 16, 2026 00:00 UTC

Advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) with MET exon 14 (METEX14) skipping alterations or MET amplification

Get alerted when new Advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) with MET exon 14 (METEX14) skipping alterations or MET amplification trials appear

New targeted drug shows promise for lung cancer with MET mutations